|1.||Dennis, James W: 1 article (04/2006)|
|2.||Park, Hyun-Joo: 1 article (04/2006)|
|3.||Partridge, Emily: 1 article (04/2006)|
|4.||Pawling, Judy: 1 article (04/2006)|
|5.||Wrana, Jeffrey L: 1 article (04/2006)|
|6.||Cheung, Pam: 1 article (04/2006)|
|7.||Donovan, Rob: 1 article (04/2006)|
04/01/2006 - "Hyperactivation of intracellular signaling has the potential to suppress tumor cell growth and, in this regard, DAM-1976 represents a new pharmacophore that increases basal activation of Smad2/3 and Erk, inhibits microfilament remodeling, and suppresses carcinoma cell growth."
04/01/2006 - "In Mgat5 mutant and wild-type carcinoma cells, DAM-1976 enhanced and prolonged TGF-beta- and EGF-dependent Smad2/3 and Erk activation, respectively. "
04/01/2006 - "Taking advantage of the Mgat5 mutant phenotype of accelerated receptor loss to endocytosis, we determined that DAM-1976 restored the sensitivity of Mgat5(-/-) carcinoma cells to both TGF-beta and epidermal growth factor (EGF). "
|1.||Transforming Growth Factor beta (TGF-beta)
|2.||Epidermal Growth Factor (EGF)